Prevention

What Comes After Maximum Statin If LDL Remains Above Target?

Quick answer

Add ezetimibe first — it adds about 18–25% LDL reduction on top of a statin and is supported by IMPROVE-IT. If still above target, add a PCSK9 inhibitor (evolocumab, alirocumab) for an additional 50–60% LDL reduction with MACE benefit. Bempedoic acid and inclisiran are alternatives, particularly in statin intolerance or when injection or cost barriers exist.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

IMPROVE-IT (2015)

PMID 26039521

18,144 post-ACS patients

Ezetimibe + simvastatin reduced 7-year MACE 6.4% relative vs simvastatin alone (HR 0.936, p=0.016). LDL 70 → 54 mg/dL.

FOURIER (2017)

PMID 28304224

27,564 with ASCVD on statin

Evolocumab reduced MACE 15% (HR 0.85). LDL 92 → 30 mg/dL. Benefit grew over time.

CLEAR Outcomes (2023)

PMID 36876740

13,970 statin-intolerant, high CV risk

Bempedoic acid reduced MACE 13% (HR 0.87). LDL dropped 21% from baseline.

Practical decision algorithm

IfThen
ASCVD on max statin, LDL ≥70 (or ≥55 in very high risk)Add ezetimibe 10 mg daily; recheck LDL in 6 weeks.
Still above target after statin + ezetimibeAdd PCSK9 inhibitor (evolocumab 140 mg q2w or alirocumab 75–150 mg q2w).
Statin intolerant after 2 statinsEzetimibe + bempedoic acid 180 mg daily; add PCSK9 inhibitor if target unmet.
Adherence barrier on injectionsInclisiran 284 mg SC at 0, 3 months then q6 months — siRNA durable LDL reduction.
HoFH or severe geneticCombination statin + ezetimibe + PCSK9 + lomitapide/evinacumab — refer to lipid specialist.

Guideline position

2018 AHA/ACC cholesterol guideline: add ezetimibe (Class 2a) then PCSK9 inhibitor (Class 2a) in very-high-risk ASCVD with LDL ≥70 on maximum statin. 2019 ESC/EAS: target LDL <55 in very-high-risk; escalate with ezetimibe then PCSK9 inhibitor.

Contraindications and cautions

  • Pregnancy (PCSK9 inhibitor — limited data; statins and ezetimibe contraindicated)
  • Active hepatic disease
  • Prior severe hypersensitivity to monoclonal antibody (PCSK9i)
  • Gout for bempedoic acid — monitor urate; elevates uric acid

Frequently asked questions

Is LDL <55 a real target or aspirational?
Real — ESC 2019 and ACC 2022 expert consensus support <55 mg/dL in very-high-risk ASCVD, with even lower targets (<40) in recurrent events. Each 39 mg/dL reduction = ~22% event reduction.
Does ApoB or Lp(a) change the plan?
ApoB <65 mg/dL aligns with LDL <70. Elevated Lp(a) adds residual risk; PCSK9 inhibitors lower Lp(a) modestly. Specific Lp(a)-lowering therapies (olpasiran, pelacarsen) are in phase 3.
How does inclisiran compare to monoclonal PCSK9i?
Similar LDL lowering (50–55%). Twice-yearly dosing after initial two doses. Awaiting MACE outcomes (ORION-4). Reasonable for adherence challenges; cost and access vary.
Should I use CAC to decide on PCSK9 inhibitor?
CAC doesn't drive PCSK9i use for secondary prevention (already ASCVD-established). In primary prevention with familial hypercholesterolemia or markedly high LDL, elevated CAC strengthens the case.
Bempedoic acid — why not first-line?
Smaller LDL reduction (~21%) than PCSK9i and cost similar to ezetimibe but with fewer decades of safety data. Best niche: statin intolerance or add-on when PCSK9i not accessible.

Further reading

Clinical Reasoning

Acute Coronary Syndrome: STEMI and NSTEMI Management Updates for 2026

Methodology

Shared Decision-Making with Complex Evidence: A Practical Guide

Clinical Reasoning

Polypharmacy in Elderly Patients: An Evidence-Based Deprescribing Framework

Back to all decision points